Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Aclarion Inc
ACON
Healthcare
Biotechnology
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the...
spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ACON)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on May 23, 2023 7:30am
New Press Release - Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader AdvocacyAclarion to Participate in Upcoming ISASS 2023 on June 1-3, 2023 in San Francisco, CA Where Their Health Economics Outcomes Abstract...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on May 23, 2023 7:00am
New Press Release - Aclarion, Inc. Announces Delayed 10-Q Filing
BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on May 19, 2023 7:30am
New Press Release - Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization PaymentsFinancing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of Definitive Growth CapitalBROOMFIELD, CO, May 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc....
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on May 02, 2023 7:00am
New Press Release - Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain
Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 28, 2023 11:20am
New Press Release - Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023
Nociscan™ is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological low back pain.Nociscan provides decision support to help bridge a major diagnostic void.Sigurd Berven, MD will speak to groundbreaking clinical and economic evidence...
read article.
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2023 1:15pm
ACON ..... Volume has been declining for the last 3/4 hr
just an observation No position
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2023 1:13pm
ACON.....so much for the $1.67 support line...
better get going or next support is ~ $1.30 Ruh Roh ; )
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2023 12:51pm
ACON..... After all the a.m churning.....
The $1.67 support line is still an important line Watching with NO Position
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2023 11:01am
ACON .....Now in PB mode ...has to hold and rally at support
$1.84....next after that would be $1.66....then it get real slipppery
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2023 10:28am
ACON ... Halt #7
No position
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2023 10:16am
ACON..... Yehaaaaa !!!
Halt #6....on the upswing Cheers !
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2023 10:04am
ACON ....Halted for the 4th time this a.m
Cheers !
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Apr 24, 2023 10:01am
ACON.....Early a.m runner on a tear
1st Scalp of the day .... Cheers !
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
A Canadian Company Focused on Exploring and Developing Saskatchewan’s Diamond Resources
Have you held units of a TD mutual fund, other than through a discount broker? Learn more.
The world's largest undeveloped diamond deposit is trading at a discount